Kairos Pharma shareholders approve reverse stock split and equity plan amendments

Kairos Pharma, LTD.

Stockholders approved reverse stock split at ratio between 1:3 and 1:250, with board discretion on timing.
Amendment to certificate of incorporation passed with 11,232,321 for, 1,945,235 against, 272,950 abstain.
Equity incentive plan increased by 5M shares plus 5% annual evergreen for 10 years; approved with 7,067,866 for.
All four director nominees elected; auditor Weinberg & Company ratified; advisory executive compensation approved.
Annual meeting had 62.81% voter turnout; 13,450,506 shares voted out of 21,411,198 eligible.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.